Sonim Q4 preliminary: $15.2M revenue (+13% YoY), net loss $20-24M (vs $3M Q3), cash $5M

DNA X, Inc.

2024-FY EPS reported -$7.13 revenue$58,298,000

Revenue ~$15.2M, up 13% YoY from $13.4M and up sequentially from $15.0M in Q3.
GAAP net loss expected $20-24M, compared to $3M in Q3, driven by $12M R&D for new product launches.
Also: $4M COGS adjustment, $2M credit loss provision, $1M restructuring charge.
Cash expected ~$5M at year-end; launched new 5G hotspots and smartphones with Verizon, Telstra, Bell Canada.
Expanded global distribution to Europe, Africa, Australia; new manufacturing in Taiwan (TAA certified) and Vietnam.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.